Clinical Trials Logo

Androgen Receptor Positive clinical trials

View clinical trials related to Androgen Receptor Positive.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05839119 Recruiting - Clinical trials for Urothelial Carcinoma Bladder

Targeting Androgen Signaling in Urothelial Cell Carcinoma - Neoadjuvant

TASUC-Neo
Start date: October 2, 2023
Phase: Phase 1
Study type: Interventional

This study is for patients who have bladder cancer that invades into the muscle wall of the bladder. The standard treatment for patients with muscle invasive bladder cancer is to give 4 cycles of chemotherapy with the drugs cisplatin and gemcitabine, then to do an operation to remove the bladder (cystectomy). In this study, the investigators will test participants' bladder cancer to see if their bladder cancer has a receptor for testosterone inside the bladder cancer cells. If it has the testosterone receptor participants will receive a medication called Degarelix that lowers testosterone levels in the blood. Degarelix will be given during the period that participants are receiving the standard of care chemotherapy drugs gemcitabine and cisplatin. The purpose of this study is to evaluate the effects, good and bad, of adding Degarelix to standard chemotherapy for patients with bladder cancer that have the testosterone receptor.